Author information from the last article
Hjertemedisinsk avdeling
Oslo universitetssykehus, Ullevål sykehus
og
Institutt for klinisk medisin
Universitetet i Oslo
Forfatterbidrag: projektledelse, hjelp med nettverksbygging, utarbeiding av manuskriptet og godkjenning av den innsendte manusversjonen.
Dan Atar er spesialist i indremedisin og hjertesykdommer, overlege, professor og forskningsleder.
Articles by Dan Atar
Recurrent pericarditis
- Peter M. Andel,
- Pål Aukrust,
- Jostein Gleditsch,
- Einar Gude,
- Glenn Haugeberg,
- Sverre Høie,
- Tore Salte,
- Kjetil Steine,
- Dan Atar
31.05.2023:
Pericarditis is an important differential diagnosis in patients with chest pain. The two most common causes in the developed world are idiopathic pericarditis and inflammation following cardiac surgery or myocardial infarction. Recurrence of pericarditis affects up to 30 % of patients, half of whom...
Intensification of antithrombotic therapy for chronic atherosclerosis
- Marita Knudsen Pope,
- Waleed Ghanima,
- Dan Atar
24.06.2020:
Intensification of antithrombotic therapy can reduce morbidity and mortality in patients with established atherosclerosis. The treatment strategy ought to be incorporated into Norwegian guidelines. Atherosclerosis causes a weakening or stenosis of the arterial walls and is a pathophysiological cause...
Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe COVID-19?
- Anne Hege Aamodt,
- Marte H. Bjørk,
- Erling A. Tronvik,
- Eirik Alnes Buanes,
- Lars Jacob Stovner,
- Dan Atar
14.05.2020:
Hypertension and diabetes mellitus are risk factors for a severe course of COVID-19. Questions have been raised as to whether this association is related to the use of ACE inhibitors and angiotensin II receptor blockers. People with hypertension and diabetes mellitus are more prone to a severe...
New anticoagulants in combination with antiplatelet agents
- Henriette Johansen,
- Ole-Christian Walter Rutherford,
- Anne Hege Aamodt,
- David Russell,
- Dan Atar,
- Waleed Ghanima
11.10.2016:
The use of new, direct anticoagulants is increasing. Data from both controlled trials and clinical practice have shown that these drugs are as efficacious and safe as warfarin for deep vein thrombosis and pulmonary embolism, and as stroke prophylaxis for patients with atrial fibrillation. But what...
New oral anticoagulants – a review
- Waleed Ghanima,
- Dan Atar,
- Per Morten Sandset
01.10.2013:
Anticoagulation treatment is necessary for preventing and treating a number of thromboembolic conditions. It is well known that warfarin treatment provides effective protection against thrombosis, but the treatment is made difficult by the small therapeutic window, wide dose-response variation, many...